Company Overview - Maze Therapeutics aims to leverage human genetics to improve patient outcomes, particularly focusing on chronic kidney disease, which affects over 800 million people globally and is the 9th leading cause of death [2] Industry Context - Chronic kidney disease is characterized by a lack of innovation and precision medicine approaches, creating a significant opportunity for companies like Maze Therapeutics to fill this gap [2] Product Pipeline - The lead product, MZE829, targets APOL1-mediated kidney disease, with an estimated 1 million individuals in the U.S. who could benefit from this treatment. The company is currently enrolling patients for Phase II trials, expecting to present clinical proof-of-concept data by Q1 2026 [3] - The second program, MZE782, focuses on SLC6A19 and is being developed for phenylketonuria (PKU). The company has already demonstrated clinical proof of mechanism for this approach in chronic kidney disease [4]